Search bioRxiv⌕ Search

Biology subjects

Serna, V. A.

Publications and source records attributed to Serna, V. A..

3 recordsLinked to original sources

Cell type-specific enhancers regulate IL-22 expression in innate and adaptive lymphoid cells

IL-22, a signature cytokine of type 3 lymphoid cells, mediates epithelial homeostasis and protective pathogen responses in barrier tissues, while its deregulated expression drives chronic inflammation associated with colitis and psoriasis. Despite its therapeutic value, little is known about regulatory elements for IL-22 expression. We identify two conserved enhancers, E22-1 and E22-2, which differentially regulate Il22 in type 3 lymphoid subsets. These enhancers are required for steady-state expression of gut antimicrobial peptides, protection from C. rodentium infection, and development of IL-22-mediated psoriasis. E22-1 resembles many known enhancers, functioning in both Th-ILC counterparts. However, E22-2 is only required for IL-22 expression in ILC3s. Its ILC3 restriction relies on multiple Runx3 sites, combined with the lack of a functional ROR{gamma}t motif, which is present in E22-1. Thus, although responding to similar stimuli, type 3 lymphoid cells use distinct cis-elements for IL-22 expression, with E22-2 likely serving as a homeostatic enhancer in barrier tissues.

immunology↗

Patient-derived xenograft studies of fumarate hydratase (FH) -deficient uterine leiomyoma subtype.

Uterine leiomyoma (LM) is the most common benign gynecological tumor in premenopausal women. Our previous patient-derived xenograft (PDX) studies established that 17{beta}-estradiol (E2) and progesterone (P4) stimulate the growth of the two most prevalent subtypes, MED12 mutant (MED12-LM) and HMGA2 overexpressing LMs (HMGA2-LM), via proliferation and hypertrophy of smooth muscle tumor cells (SMTCs). In addition, tumor-associated fibroblasts (TAFs) that do not carry MED12 mutations also contribute to the growth of MED12-LM by secreting extracellular matrix (ECM) proteins. In this study, we investigated the growth control of the fumarate hydratase (FH) deficient LM (FH-LM) subtype, utilizing the PDX model. We identified an FH-negative case with conventional leiomyoma histology. The overexpression of aldo-keto reductase family 1 member B10 (AKR1B10) confirmed the FH deficiency. Like MED12-LM, FH-LM comprised two major cell types: 54.4% SMTCs and 43.3% TAFs. Furthermore, the TAFs expressed FH. The FH-LM PDXs grew in response to E2 and P4 via proliferation and hypertrophy of SMTCs, similar to MED12-LM and HMGA2-LM. While E2 alone did not stimulate growth, E2 was essential for sensitizing FH-deficient SMTCs to P4 by upregulating progesterone receptor (PGR). Our current study established that the growth of the three most prevalent LM subtypes, MED12-LM, HMGA2-LM, and FH-LM, depends on E2 and P4. Thus, selective progesterone receptor modulators (SPRMs) should be an effective treatment option for most symptomatic LM patients.

genetics↗

SIX1 cooperates with RUNX1 and SMAD4 in cell fate commitment of Müllerian duct epithelium

During female mammal reproductive tract development, epithelial cells of the lower Mullerian duct are committed to become stratified squamous epithelium of vagina and ectocervix, when the expression of {Delta}Np63 transcription factor is induced by mesenchymal cells. The absence of {Delta}Np63 expression leads to adenosis, the putative precursor of vaginal adenocarcinoma. Our previous studies with genetically engineered mouse models have established that fibroblast growth factor (FGF)/mitogen-activated protein kinase (MAPK), bone morphogenetic protein (BMP)/SMAD, and activin A/runt related transcription factor 1 (RUNX1) signaling pathways are independently required for {Delta}Np63 expression in Mullerian duct epithelium (MDE). Here we report that sine oculis homeobox homolog 1 (SIX1) plays a critical role in the activation of {Delta}Np63 locus in MDE as a downstream transcription factor of mesenchymal signals. In mouse developing reproductive tract, SIX1 expression was restricted to MDE of the future cervix and vagina. SIX1 expression was totally absent in SMAD4 null MDE and was reduced in RUNX1 null and FGFR2 null MDE, indicating that SIX1 is under the control of vaginal mesenchymal factors, BMP4, activin A and FGF7/10. Furthermore, Six1, Runx1 and Smad4 gene-dose-dependently activated {Delta}Np63 expression in MDE within vaginal fornix. Using a mouse model of diethylstilbestrol (DES)-associated vaginal adenosis, we found DES action through epithelial estrogen receptor (ESR1) down-regulates SIX1 and RUNX1 in MDE within the vaginal fornix. This study establishes that the vaginal/ectocervical cell fate of MDE is regulated by a collaboration of multiple transcription factors including SMAD4, SIX1 and RUNX1, and the down-regulation of these key transcription factors leads to vaginal adenosis.\n\nAuthor SummaryIn embryogenesis, differentiation fate of cells is specified through constant communication between neighboring cells. In this study, we investigated the molecular mechanism of epithelial cell fate commitment in the lower female reproductive organs utilizing mouse genetic models. The cell fate of epithelial cells in the uterus, cervix and vagina is directed by signaling from mesenchymal cells. We demonstrated that within the epithelial cells of the developing vagina, signals from mesenchymal cells are integrated into activities of transcription factors including SMAD4, RUNX1 and SIX1, which dose-dependently co-operate in the determination of vaginal epithelial cell fate. Disruption of these processes alters the cell fate from vaginal to uterine epithelium, resulting in a condition called vaginal adenosis, a putative precursor of vaginal adenocarcinoma. Women exposed to diethylstilbestrol (DES) in the womb have about 40 times the risk of developing vaginal adenocarcinoma. We determined that developmental exposure to DES induces vaginal adenosis by repressing SIX1 and RUNX1 through ESR1 in the epithelial cells. This discovery enhances the understanding of how early-life events, such as exposure to endocrine disruptors, causes vaginal adenosis, and thus may contribute to the prevention and therapeutic treatment of idiopathic vaginal adenocarcinoma.

developmental biology↗